[0038] In some embodiments, the present disclosure provides an anti-CD96 antibody wherein the antibody comprises a light chain variable domain (V_L) amino acid sequence having at least 90% identity to a sequence selected from SEQ ID NO: 70, and 377-409; and/or a heavy chain variable domain (V_H) amino acid sequence having at least 90% identity to a sequence selected from SEQ ID NO: 71, and 410-439.

[0039] In some embodiments, the present disclosure provides an anti-CD96 antibody wherein the antibody comprises:

[0040] (a) a light chain variable domain (V_L) amino acid sequence having at least 90% identity to SEQ ID NO: 12, and/or a heavy chain variable domain (V_H) amino acid sequence having at least 90% identity to SEQ ID NO: 40;

[0041] (b) a light chain variable domain (V_L) amino acid sequence having at least 90% identity to SEQ ID NO: 36, and/or a heavy chain variable domain (V_H) amino acid sequence having at least 90% identity to SEQ ID NO: 64;

[0042] (c) a light chain variable domain (V_L) amino acid sequence having at least 90% identity to SEQ ID NO: 68, and/or a heavy chain variable domain (V_H) amino acid sequence having at least 90% identity to a sequence selected from SEQ ID NOs: 69, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 460, 461, 462, 463, or 464; or

[0043] (d) a light chain variable domain (V_L) amino acid sequence having at least 90% identity to SEQ ID NO: 70, and/or a heavy chain variable domain (V_H) amino acid sequence having at least 90% identity to SEQ ID NO: 71.

[0044] In some embodiments, the present disclosure provides an anti-CD96 antibody wherein the antibody comprises:

[0045] (a) a light chain (LC) amino acid sequence having at least 90% identity to a sequence selected from SEQ ID NO: 440, 441, 442, 443, 444, 445, or 446; and/or a heavy chain (HC) amino acid sequence having at least 90% identity to a sequence selected from SEQ ID NO: 447, 448, 449, 450, 451, 452, 453, 484, 485, 486, 487, 488, 489, or 490;

[0046] (b) a light chain (LC) amino acid sequence having at least 90% identity to SEQ ID NO: 440; and/or a heavy chain (HC) amino acid sequence having at least 90% identity to SEQ ID NO: 447 or 484;

[0047] (c) a light chain (LC) amino acid sequence having at least 90% identity to SEQ ID NO: 446; and/or a heavy chain (HC) amino acid sequence having at least 90% identity to SEQ ID NO: 453 or 490;

[0048] (d) comprises a light chain (LC) amino acid sequence having at least 90% identity to SEQ ID NO: 454, and/or a heavy chain (HC) amino acid sequence having at least 90% identity to a sequence selected from SEQ ID NO: 455, 456, 457, 458, 459, 465, 466, 467, 468, 469, 491, 492, 493, 494, or 495; or

[0049] (e) a light chain (LC) amino acid sequence having at least 90% identity to SEQ ID NO: 470; and/or a heavy chain (HC) amino acid sequence having at least 90% identity to SEQ ID NO: 471 or 501.

[0050] In some embodiments, the present disclosure provides an anti-CD96 antibody comprising:

[0051] (a) a first light chain hypervariable region (HVR-L1) of SEQ ID NO: 13, a second light chain hypervariable region (HVR-L2) of SEQ ID NO: 14, and a third light chain hypervariable region (HVR-L3) of SEQ ID NO: 15; and/or a first heavy chain hypervariable region (HVR-H1) of SEQ ID NO: 72, a second heavy chain hypervariable region (HVR-H2) of SEQ ID NO: 107, and a third heavy chain hypervariable region (HVR-H3) of SEQ ID NO: 203; or

[0052] (b) a first light chain hypervariable region (HVR-L1) of SEQ ID NO: 308, a second light chain hypervariable region (HVR-L2) of SEQ ID NO: 325, a third light chain hypervariable region (HVR-L3) of SEQ ID NO: 335, and/or a first heavy chain hypervariable region (HVR-H1) of SEQ ID NO: 344, a second heavy chain hypervariable region (HVR-H2) of SEQ ID NO: 369, and a third heavy chain hypervariable region (HVR-H3) of SEQ ID NO: 372.

[0053] In some embodiments, the present disclosure provides an anti-CD96 antibody comprising:

[0054] (a) a first light chain hypervariable region (HVR-L1) of SEQ ID NO: 13, a second light chain hypervariable region (HVR-L2) of SEQ ID NO: 14, a third light chain hypervariable region (HVR-L3) of SEQ ID NO: 15; and/or a first heavy chain hypervariable region (HVR-H1) of SEQ ID NO: 41, a second heavy chain hypervariable region (HVR-H2) of SEQ ID NO: 42, and a third heavy chain hypervariable region (HVR-H3) of SEQ ID NO: 43;

[0055] (b) a first light chain hypervariable region (HVR-L1) of SEQ ID NO: 13, a second light chain hypervariable region (HVR-L2) of SEQ ID NO: 14, a third light chain hypervariable region (HVR-L3) of SEQ ID NO: 15; and/or a first heavy chain hypervariable region (HVR-H1) of SEQ ID NO: 95, a second heavy chain hypervariable region (HVR-H2) of SEQ ID NO: 42, and a third heavy chain hypervariable region (HVR-H3) of SEQ ID NO: 43;

[0056] (c) a first light chain hypervariable region (HVR-L1) of SEQ ID NO: 13, a second light chain hypervariable region (HVR-L2) of SEQ ID NO: 14, a third light chain hypervariable region (HVR-L3) of SEQ ID NO: 15; and/or a first heavy chain hypervariable region (HVR-H1) of SEQ ID NO: 41, a second heavy chain hypervariable region (HVR-H2) of SEQ ID NO: 108, and a third heavy chain hypervariable region (HVR-H3) of SEQ ID NO: 43;

[0057] (d) a first light chain hypervariable region (HVR-L1) of SEQ ID NO: 13, a second light chain hypervariable region (HVR-L2) of SEQ ID NO: 14, a third light chain hypervariable region (HVR-L3) of SEQ ID NO: 15; and/or a first heavy chain hypervariable region (HVR-H1) of SEQ ID NO: 41, a second heavy chain hypervariable region (HVR-H2) of SEQ ID NO: 112, and a third heavy chain hypervariable region (HVR-H3) of SEQ ID NO: 43;

[0058] (e) a first light chain hypervariable region (HVR-L1) of SEQ ID NO: 13, a second light chain hypervariable region (HVR-L2) of SEQ ID NO: 14, a third light chain hypervariable region (HVR-L3) of SEQ ID NO: 15; and/or a first heavy chain hypervariable region (HVR-H1) of SEQ ID NO: 41, a second heavy chain hypervariable region (HVR-H2) of SEQ ID NO: 190, and a third heavy chain hypervariable region (HVR-H3) of SEQ ID NO: 43;

[0059] (f) a first light chain hypervariable region (HVR-L1) of SEQ ID NO: 13, a second light chain hyper-